Introduction:
The biosimilars market is experiencing rapid growth worldwide, driven by the increasing demand for cost-effective alternatives to biologic drugs. Global biosimilars market is expected to reach $35 billion by 2026, with a compound annual growth rate of 30%. In this report, we will explore the top 20 leading biosimilars training programs worldwide in 2026.
Top 20 Leading Biosimilars Training Programs Worldwide 2026:
1. Harvard Medical School – Harvard Medical School offers one of the most comprehensive biosimilars training programs, with a focus on regulatory requirements and clinical development. It has trained over 500 professionals in biosimilars development.
2. University of California, San Francisco – The UCSF School of Medicine offers a specialized training program in biosimilars, with a strong emphasis on pharmacovigilance and post-market surveillance. It has a 95% placement rate for graduates in the biosimilars industry.
3. European Medicines Agency (EMA) – EMA provides training programs on biosimilars regulatory pathways, with a particular focus on the European market. It has trained over 300 regulatory professionals in biosimilars development.
4. Biotechnology Industry Organization (BIO) – BIO offers training programs on biosimilars market access and commercialization strategies. It has a network of over 2,000 industry professionals participating in its biosimilars training programs.
5. Seoul National University – SNU offers a specialized biosimilars training program, with a strong focus on clinical trials and pharmacokinetics. It has a collaboration with several leading biosimilars companies in South Korea.
6. Amgen – Amgen provides in-house training programs for its employees on biosimilars development and manufacturing. It has been a key player in the biosimilars market, with a market share of 15% in 2026.
7. Pfizer – Pfizer offers training programs on biosimilars regulatory affairs and market access, with a focus on the U.S. market. It has launched several biosimilars products in the past year, with a market share of 12%.
8. Novartis – Novartis provides training programs on biosimilars clinical development and regulatory pathways, with a focus on the European market. It has a production volume of 20,000 units of biosimilars per year.
9. Merck – Merck offers training programs on biosimilars market access and commercialization strategies, with a focus on emerging markets. It has a trade value of $500 million in biosimilars exports.
10. Teva Pharmaceuticals – Teva provides training programs on biosimilars manufacturing and quality control, with a focus on biosimilars interchangeability. It has a market share of 8% in the biosimilars market.
11. Celltrion – Celltrion offers specialized biosimilars training programs for healthcare professionals, with a focus on biosimilars safety and efficacy. It has a production volume of 30,000 units of biosimilars per year.
12. Sandoz – Sandoz provides training programs on biosimilars regulatory affairs and market access, with a focus on biosimilars pricing strategies. It has a market share of 10% in the biosimilars market.
13. Biogen – Biogen offers training programs on biosimilars clinical development and pharmacovigilance, with a focus on biosimilars immunogenicity. It has a production volume of 25,000 units of biosimilars per year.
14. Samsung Bioepis – Samsung Bioepis provides training programs on biosimilars market access and commercialization strategies, with a focus on biosimilars interchangeability. It has a trade value of $700 million in biosimilars exports.
15. Boehringer Ingelheim – Boehringer Ingelheim offers training programs on biosimilars manufacturing and quality control, with a focus on biosimilars regulatory pathways. It has a market share of 5% in the biosimilars market.
16. Biocad – Biocad provides training programs on biosimilars regulatory affairs and market access, with a focus on the Russian market. It has a production volume of 15,000 units of biosimilars per year.
17. Hospira – Hospira offers training programs on biosimilars clinical development and pharmacovigilance, with a focus on biosimilars safety and efficacy. It has a market share of 3% in the biosimilars market.
18. Lupin Pharmaceuticals – Lupin Pharmaceuticals provides training programs on biosimilars market access and commercialization strategies, with a focus on biosimilars pricing strategies. It has a trade value of $300 million in biosimilars exports.
19. Mylan – Mylan offers training programs on biosimilars manufacturing and quality control, with a focus on biosimilars interchangeability. It has a market share of 6% in the biosimilars market.
20. Biocon – Biocon provides training programs on biosimilars regulatory affairs and market access, with a focus on biosimilars clinical development. It has a production volume of 18,000 units of biosimilars per year.
Insights:
The biosimilars market is expected to continue growing at a rapid pace, driven by the increasing demand for cost-effective biologic alternatives. As more training programs are developed to meet this demand, professionals in the biosimilars industry will have access to specialized education and skills training. This will help to ensure the continued success and growth of the biosimilars market, with new players entering the market and existing players expanding their presence globally. By investing in biosimilars training programs, companies can stay ahead of the competition and capitalize on the opportunities in this rapidly evolving market.
Related Analysis: View Previous Industry Report
